Compositions and methods for inhibiting hair growth

Abstract

A method for inhibiting hair growth in mammals using compositions containing FP receptor antagonists (e.g., prostaglandin F analogs that are block activation of the FP receptor). The compositions can be applied topically to the skin and/or hair. The compositions can arrest hirsutism or hypertrichosis, reverse hirsutism and hypertrichosis, and further prevent hair growth. These compositions can also be used to protect hair from chemical or radiation-induced alopecia or hair loss. These compositions can also be used to inhibit pigmentation of the hair or skin.

1 . A method of inhibiting hair growth, the method comprising administering to a subject a safe and effective amount of at least one FP receptor antagonist. 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . A method of treating a condition, the method comprising administering to a subject a safe and effective amount of at least one FP receptor antagonist, wherein the condition is selected from at least one of hirsutism, hypertrichosis, unwanted hair, chemotherapy-related hair loss, radiation-related hair loss, hyperpigmentation, and a combination thereof. 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . The method of  claim 5 , wherein the FP receptor antagonist is administered prior to chemotherapy or radiation, and wherein the FP receptor antagonist inhibits hair growth and renders the subject less susceptible to chemotherapy-related hair loss or radiation-related hair loss. 
     
     
         13 . A method of inhibiting pigmentation of hair, skin, or both, the method comprising administering to a subject a safe and effective amount of a FP receptor antagonist. 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . A method of lightening skin, the method comprising administering to a subject a safe and effective amount of a FP receptor antagonist. 
     
     
         17 . (canceled) 
     
     
         18 . The method of  claim 1 , wherein the FP receptor antagonist is selected from:
 (a) a compound of Formula I or Formula II:   
       
         
           
           
               
               
           
         
         wherein R is selected from the group consisting of CO 2 H, C(O)NHOH, CO 2 R 1 , CH 2 OH, S(O) 2 R 1 , C(O)NHR 1 , P(O)(OR 1 )R 2 , C(O)NHS(O) 2 R 1 , and tetrazole; 
         R 1  and R 2  are independently selected from the group consisting of a hydrogen atom, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, aromatic groups, substituted aromatic groups, carbocyclic groups, substituted carbocyclic groups, heterogeneous groups, substituted heterogeneous groups, heterocyclic groups, substituted heterocyclic groups, heteroaromatic groups, and substituted heteroaromatic groups; 
         W is —CH 2 —, —O—, or —S(O) 2 —; and 
         X is halogen, lower alkyl, alkoxy, or hydrogen, 
         (b) a compound of Formula III: 
       
       
         
           
           
               
               
           
         
         wherein G is selected from the group consisting of substituted or unsubstituted C 1 -C 6 -alkyl aryl, substituted or unsubstituted C 1 -C 6 -alkyl heteroaryl, substituted or unsubstituted C 1 -C 6 -alkyl cycloalkyl, substituted or unsubstituted C 1 -C 6 -alkyl heteroaryl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 -cycloalkyl or C 3 -C 8 -heterocycloalkyl, wherein said cycloalkyl or aryl or heteroaryl groups may be fused with cycloalkyl or aryl or heteroaryl groups; 
         R 1  is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 -cycloalkyl or C 3 -C 8 -heterocycloalkyl, wherein said (hetero)cycloalkyl or aryl or heteroaryl groups may be fused with (hetero)-cycloalkyl or aryl or heteroaryl groups; 
         R 2  is H, carboxy, acyl, alkoxycarbonyl, aminocarbonyl, substituted or unsubstituted C 1 -C 5 -alkyl carboxy, substituted or unsubstituted C 1 -C 5 -alkyl acyl, substituted or unsubstituted C 1 -C 5 -alkyl alkoxycarbonyl, substituted or unsubstituted C 1 -C 5 -alkyl aminocarbonyl, substituted or unsubstituted C 1 -C 5 -alkyl acyloxy, substituted or unsubstituted C 1 -C 5 -alkyl acylamino, substituted or unsubstituted C 1 -C 5 -alkyl ureido, substituted or unsubstituted C 1 -C 5 -alkyl amino, substituted or unsubstituted C 1 -C 5 -alkyl alkoxy, substituted or unsubstituted C 1 -C 5 -alkyl sulfanyl, substituted or unsubstituted C 1 -C 5 -alkyl sulfinyl, substituted or un substituted C 1 -C 5 -alkyl sulfonyl, substituted or unsubstituted C 1 -C 5 -alkyl sulfonylamino, substituted or unsubstituted C 1 -C 5 -alkyl sulfonyloxy, substituted or unsubstituted C 1 -C 6 -alkyl, substituted or unsubstituted C 2 -C 6 -alkenyl, substituted or unsubstituted C 2 -C 6 -alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 -cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted C 1 -C 6 -alkyl aryl, substituted or unsubstituted C 2 -C 6 -alkyl heteroaryl, substituted or unsubstituted C 1 -C 6 -alkyl cycloalkyl, substituted or unsubstituted C 1 -C 6 -alkyl heterocycloalkyl, substituted or unsubstituted C 2 -C 6 -alkenyl aryl, substituted or unsubstituted C 2-6 -alkenyl heteroaryl, substituted or unsubstituted C 2 -C 6 -alkynyl aryl, or substituted or unsubstituted C 2 -C 6 -alkynyl heteroaryl, or wherein R 2  and G may form a C 3 -C 8 -cycloalkyl ring; 
         R 4  is selected from the group consisting of substituted or unsubstituted C 1 -C 6 -alkyl, substituted or unsubstituted C 2 -C 6 -alkenyl, substituted or unsubstituted C 2 -C 6 -alkynyl; and 
         n is an integer from 0 to 2; 
         (c) a compound of Formula IV:
   Y-AA 1 -AA 2 -AA 3 -AA 4 -AA 5 -AA 6 -AA 7 -AA 8 -Z  (IV
 
 
         wherein Y is attached to the amino-terminus of said peptide and is selected from the group consisting of a hydrogen atom, an acetyl group, a benzoyl group, an acyl group (R—CO—) wherein R is a hydrophobic moiety, and an aroyl group (Ar—CO—) wherein Ar is an aryl group; 
         AA 1  and AA 2  are independently selected from the group consisting of no residue, isoleucine (Ile), leucine (Leu), and related alpha-amino acids possessing hydrophobic side-chains; 
         AA 3  is selected from the group consisting of no residue, glycine (Gly), alanine (Ala), and proline (Pro); 
         AA 4  is selected from the group consisting of histidine (His), phenylalanine (Phe), tyrosine (Tyr), and tryptophan (Trp); 
         AA 5  is selected from the group consisting of arginine (Arg), ornithine (Orn), lysine (Lys), citruline, 2-, 3-, and 4-pyridylalanine, and arginine surrogates; 
         AA 6  is selected from the group consisting of aspartic acid (Asp), asparagine (Asn), glutamic acid (Glu), glutamine (Gln), serine (Ser), 3-amino-5-phenylpentanoic acid, and Phe; 
         AA 7  is selected from the group consisting of no residue, Tyr, and Phe; 
         AA 8  is selected from the group consisting of no residue, Lys, Leu, and Tyr; and 
         Z is attached to the carboxy-terminus of said peptide and is selected from the group consisting of, a hydroxyl group, NH 2 , and aromatic and aliphatic amines; and 
         (d) a compound of Formula V:
   Y-BTM-AA1-AA2-AA3-Z  (V)
 
 
         wherein Y is attached to the amino-terminus of the peptide and is selected from the group consisting of a hydrogen atom, an acyl group (R—CO—) wherein R is a hydrophobic moiety, and an aroyl group (Ar—CO—) wherein Ar is an aryl group; 
         BTM (beta turn mimetic) is a dipeptide surrogate; 
         AA 1  is selected from the group consisting of Arg, Orn, Lys, citruline, 2-, 3-, and 4-pyridylalanine, and arginine surrogates; 
         AA 2  is selected from the group consisting of Asp, Asn, Glu, Gln, Ser, 3-amino-5-phenylpentanoic acid, and Phe; 
         AA 3  is selected from the group consisting of no residue, Tyr, and Phe; and 
         Z is selected from the group consisting of no residue, a hydroxyl group, NH 2 , and aromatic, heteroaromatic, and aliphatic amines. 
       
     
     
         19 . The method of  claim 18 , wherein R 1  and R 2  are selected from the group consisting of CH 3 , C 2 H 5 , and C 3 H 7 . 
     
     
         20 . The method of  claim 18 , wherein R is selected from the group consisting of CO 2 H, CO 2 CH 3 , C(O)NHC 2 H 5 , CO 2 C 2 H 5 , CO 2 C 3 H 7 , CO 2 C 4 H 9 , CO 2 C 3 H 7 O 2 , and C(O)NHS(O) 2 R 1 . 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . The method of  claim 18 , wherein X is methoxy, methyl, or halogen. 
     
     
         24 . (canceled) 
     
     
         25 . (canceled) 
     
     
         26 . The method of  claim 18 , wherein X is F. 
     
     
         27 . The method of  claim 18 , wherein the compound is of Formula I or II and is selected from the group consisting of a 11-deoxy-16-fluoro PGF 2α  analog, 
       
         
           
           
               
               
           
         
       
     
     
         28 . (canceled) 
     
     
         29 . (canceled) 
     
     
         30 . (canceled) 
     
     
         31 . (canceled) 
     
     
         32 . The method of  claim 18 , wherein the compound is of Formula III and G is an aryl group, a substituted or unsubstituted phenyl, or a biphenyl. 
     
     
         33 . (canceled) 
     
     
         34 . (canceled) 
     
     
         35 . The method of  claim 18 , wherein the compound is the following: 
       
         
           
           
               
               
           
         
       
     
     
         36 . (canceled) 
     
     
         37 . The method of  claim 18 , wherein the FP receptor antagonist is of Formula IV and comprises a polypeptide of SEQ ID NO: 1. 
     
     
         38 . (canceled) 
     
     
         39 . A pharmaceutical composition comprising:
 A) an FP receptor antagonist;   B) a carrier; and   C) at least one activity enhancer selected from the group consisting of:
 i) hair growth inhibitor; 
 ii) skin lightening agent; 
 iii) hirsutism treatment agent; 
 iv) preventative of chemotherapy-related hair loss or radiation-related hair loss; and 
 v) penetration enhancer. 
   
     
     
         40 . The composition of  claim 39 , wherein the FP receptor antagonist is selected from:
 (a) a compound of Formula I or Formula II:   
       
         
           
           
               
               
           
         
         wherein R is selected from the group consisting of CO 2 H, C(O)NHOH, CO 2 R 1 , CH 2 OH, S(O) 2 R 1 , C(O)NHR 1 , P(O)(OR 1 )R 2 , C(O)NHS(O) 2 R 1 , and tetrazole; 
         R 1  and R 2  are independently selected from the group consisting of a hydrogen atom, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, aromatic groups, substituted aromatic groups, carbocyclic groups, substituted carbocyclic groups, heterogeneous groups, substituted heterogeneous groups, heterocyclic groups, substituted heterocyclic groups, heteroaromatic groups, and substituted heteroaromatic groups; 
         W is —CH 2 —, —O—, or —S(O) 2 —; and 
         X is halogen; 
         (b) a compound of Formula III: 
       
       
         
           
           
               
               
           
         
         wherein G is selected from the group consisting of substituted or unsubstituted C 1 -C 6 -alkyl aryl, substituted or unsubstituted C 1 -C 6 -alkyl heteroaryl, substituted or unsubstituted C 1 -C 6 -alkyl cycloalkyl, substituted or unsubstituted C 1 -C 6 -alkyl heteroaryl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 -cycloalkyl or C 3 -C 8 -heterocycloalkyl, wherein said cycloalkyl or aryl or heteroaryl groups may be fused with cycloalkyl or aryl or heteroaryl groups; 
         R 1  is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 -cycloalkyl or C 3 -C 8 -heterocycloalkyl, wherein said (hetero)cycloalkyl or aryl or heteroaryl groups may be fused with (hetero)-cycloalkyl or aryl or heteroaryl groups; 
         R 2  is H, carboxy, acyl, alkoxycarbonyl, aminocarbonyl, substituted or unsubstituted C 1 -C 5 -alkyl carboxy, substituted or unsubstituted C 1 -C 5 -alkyl acyl, substituted or unsubstituted C 1 -C 5 -alkyl alkoxycarbonyl, substituted or unsubstituted C 1 -C 5 -alkyl aminocarbonyl, substituted or unsubstituted C 1 -C 5 -alkyl acyloxy, substituted or unsubstituted C 1 -C 5 -alkyl acylamino, substituted or unsubstituted C 1 -C 5 -alkyl ureido, substituted or unsubstituted C 1 -C 5 -alkyl amino, substituted or unsubstituted C 1 -C 5 -alkyl alkoxy, substituted or unsubstituted C 1 -C 5 -alkyl sulfanyl, substituted or unsubstituted C 1 -C 5 -alkyl sulfinyl, substituted or unsubstituted C 1 -C 5 -alkyl sulfonyl, substituted or unsubstituted C 1 -C 5 -alkyl sulfonylamino substituted or unsubstituted C 1 -C 5 -alkyl sulfonyloxy, substituted or unsubstituted C 1 -C 6 -alkyl, substituted or unsubstituted C 2 -C 6 -alkenyl, substituted or unsubstituted C 2 -C 6 -alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 -cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted C 1 -C 6 -alkyl aryl, substituted or unsubstituted C 2 -C 6 -alkyl heteroaryl, substituted or unsubstituted C 1 -C 6 -alkyl cycloalkyl, substituted or unsubstituted C 1 -C 6 -alkyl heterocycloalkyl, substituted or unsubstituted C 2 -C 6 -alkenyl aryl, substituted or unsubstituted C 2-6 -alkenyl heteroaryl, substituted or unsubstituted C 2 -C 6 -alkynyl aryl, or substituted or unsubstituted C 2 -C 6 -alkynyl heteroaryl, or wherein R 2  and G may form a C 3 -C 8 -cycloalkyl ring; 
         R 4  is selected from the group consisting of substituted or unsubstituted C 1 -C 6 -alkyl, substituted or unsubstituted C 2 -C 6 -alkenyl, substituted or unsubstituted C 2 -C 6 -alkynyl; and 
         n is an integer from 0 to 2; 
         (c) a compound of Formula IV:
   Y-AA 1 -AA 2 -AA 3 -AA 4 -AA 5 -AA 6 -AA 7 -AA 8 -Z  (IV)
 
 
         wherein Y is attached to the amino-terminus of said peptide and is selected from the group consisting of a hydrogen atom, an acetyl group, a benzoyl group, an acyl group (R—CO—) wherein R is a hydrophobic moiety, and an aroyl group (Ar—CO—) wherein Ar is an aryl group; 
         AA 1  and AA 2  are independently selected from the group consisting of no residue, isoleucine (Ile), leucine (Leu), and related alpha-amino acids possessing hydrophobic side-chains: 
         AA 3  is selected from the group consisting of no residue, glycine (Gly), alanine (Ala), and proline (Pro); 
         AA 4  is selected from the group consisting of histidine (His), phenylalanine (Phe), tyrosine (Tyr), and tryptophan (Trp); 
         AA 5  is selected from the group consisting of arginine (Arg), ornithine (Orn), lysine (Lys), citruline, 2-, 3-, and 4-pyridylalanine, and arginine surrogates; 
         AA 6  is selected from the group consisting of aspartic acid (Asp), asparagine (Asn), glutamic acid (Glu), glutamine (Gln), serine (Ser), 3-amino-5-phenylpentanoic acid, and Phe; 
         AA 7  is selected from the group consisting of no residue, Tyr, and Phe; 
         AA 8  is selected from the group consisting of no residue, Lys, Leu, and Tyr; and 
         Z is attached to the carboxy-terminus of said peptide and is selected from the group consisting of, a hydroxyl group, NH 2 , and aromatic and aliphatic amines; and 
         (d) a compound of Formula V:
   Y-BTM-AA1-AA2-AA3-Z  (V)
 
 
         wherein Y is attached to the amino-terminus of the peptide and is selected from the group consisting of a hydrogen atom, an acyl group (R—CO—) wherein R is a hydrophobic moiety, and an aroyl group (Ar—CO—) wherein Ar is an aryl group; 
         BTM (beta turn mimetic) is a dipeptide surrogate; 
         AA 1  is selected from the group consisting of Arg, Orn, Lys, citruline, 2-, 3-, and 4-pyridylalanine, and arginine surrogates; 
         AA 2  is selected from the group consisting of Asp, Asn, Glu, Gln, Ser, 3-amino-5-phenylpentanoic acid, and Phe; 
         AA 3  is selected from the group consisting of no residue, Tyr, and Phe; and 
         Z is selected from the group consisting of no residue, a hydroxyl group, NH 2 , and aromatic, heteroaromatic, and aliphatic amines. 
       
     
     
         41 . (canceled) 
     
     
         42 . (canceled) 
     
     
         43 . (canceled) 
     
     
         44 . (canceled) 
     
     
         45 . (canceled) 
     
     
         46 . (canceled) 
     
     
         47 . (canceled) 
     
     
         48 . (canceled) 
     
     
         49 . (canceled) 
     
     
         50 . (canceled) 
     
     
         51 . (canceled) 
     
     
         52 . (canceled) 
     
     
         53 . (canceled) 
     
     
         54 . (canceled) 
     
     
         55 . (canceled) 
     
     
         56 . (canceled) 
     
     
         57 . (canceled) 
     
     
         58 . (canceled) 
     
     
         59 . (canceled) 
     
     
         60 . (canceled) 
     
     
         61 . The composition of  claim 39 , wherein the activity enhancer is eflornithine, deoxyArbutin, or spironolactone. 
     
     
         62 . (canceled) 
     
     
         63 . (canceled) 
     
     
         64 . The method of  claim 5 , wherein the FP receptor antagonist is selected from:
 (a) a compound of Formula I or Formula II:   
       
         
           
           
               
               
           
         
         wherein R is selected from the group consisting of CO 2 H, C(O)NHOH, CO 2 R 1 , CH 2 OH, S(O) 2 R 1 , C(O)NHR 1 , P(O)(OR 1 )R 2 , C(O)NHS(O) 2 R 1 , and tetrazole; 
         R 1  and R 2  are independently selected from the group consisting of a hydrogen atom, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, aromatic groups, substituted aromatic groups, carbocyclic groups, substituted carbocyclic groups, heterogeneous groups, substituted heterogeneous groups, heterocyclic groups, substituted heterocyclic groups, heteroaromatic groups, and substituted heteroaromatic groups; 
         W is —CH 2 —, —O—, or —S(O) 2 —; and 
         X is halogen, lower alkyl, alkoxy, or hydrogen; 
         (b) a compound of Formula III: 
       
       
         
           
           
               
               
           
         
         wherein G is selected from the group consisting of substituted or unsubstituted C 1 -C 6 -alkyl aryl, substituted or unsubstituted C 1 -C 6 -alkyl heteroaryl, substituted or unsubstituted C 1 -C 6 -alkyl cycloalkyl, substituted or unsubstituted C 1 -C 6 -alkyl heteroaryl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 -cycloalkyl or C 3 -C 8 -heterocycloalkyl, wherein said cycloalkyl or aryl or heteroaryl groups may be fused with cycloalkyl or aryl or heteroaryl groups; 
         R 1  is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 -cycloalkyl or C 3 -C 8 -heterocycloalkyl, wherein said (hetero)cycloalkyl or aryl or heteroaryl groups may be fused with (hetero)-cycloalkyl or aryl or heteroaryl groups; 
         R 2  is H, carboxy, acyl, alkoxycarbonyl, aminocarbonyl, substituted or unsubstituted C 1 -C 5 -alkyl carboxy, substituted or unsubstituted C 1 -C 5 -alkyl acyl, substituted or unsubstituted C 1 -C 5 -alkyl alkoxycarbonyl, substituted or unsubstituted C 1 -C 5 -alkyl aminocarbonyl, substituted or unsubstituted C 1 -C 5 -alkyl acyloxy, substituted or unsubstituted C 1 -C 5 -alkyl acylamino, substituted or unsubstituted C 1 -C 5 -alkyl ureido, substituted or unsubstituted C 1 -C 5 -alkyl amino, substituted or unsubstituted C 1 -C 5 -alkyl alkoxy, substituted or unsubstituted C 1 -C 5 -alkyl sulfanyl, substituted or unsubstituted C 1 -C 5 -alkyl sulfinyl, substituted or un substituted C 1 -C 5 -alkyl sulfonyl, substituted or unsubstituted C 1 -C 5 -alkyl sulfonylamino, substituted or unsubstituted C 1 -C 5 -alkyl sulfonyloxy, substituted or unsubstituted C 1 -C 6 -alkyl, substituted or unsubstituted C 2 -C 6 -alkenyl, substituted or unsubstituted C 2 -C 6 -alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 -cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted C 1 -C 6 -alkyl aryl, substituted or unsubstituted C 2 -C 6 -alkyl heteroaryl, substituted or unsubstituted C 1 -C 6 -alkyl cycloalkyl, substituted or unsubstituted C 1 -C 6 -alkyl heterocycloalkyl, substituted or unsubstituted C 2 -C 6 -alkenyl aryl, substituted or unsubstituted C 2 -C 6 -alkenyl heteroaryl, substituted or unsubstituted C 2 -C 6 -alkynyl aryl, or substituted or unsubstituted C 2 -C 6 -alkynyl heteroaryl, or wherein R 2  and G may form a C 3 -C 8 -cycloalkyl ring; 
         R 4  is selected from the group consisting of substituted or unsubstituted C 1 -C 6 -alkyl, substituted or unsubstituted C 2 -C 6 -alkenyl, substituted or unsubstituted C 2 -C 6 -alkynyl; and 
         n is an integer from 0 to 2; 
         (c) a compound of Formula IV:
   Y-AA 1 -AA 2 -AA 3 -AA 4 -AA 5 -AA 6 -AA 7 -AA 8 -Z  (IV)
 
 
         wherein Y is attached to the amino-terminus of said peptide and is selected from the group consisting of a hydrogen atom, an acetyl group, a benzoyl group, an acyl group (R—CO—) wherein R is a hydrophobic moiety, and an aroyl group (Ar—CO—) wherein Ar is an aryl group; 
         AA 1  and AA 2  are independently selected from the group consisting of no residue, isoleucine (Ile), leucine (Leu), and related alpha-amino acids possessing hydrophobic side-chains; 
         AA 3  is selected from the group consisting of no residue, glycine (Gly), alanine (Ala), and proline (Pro); 
         AA 4  is selected from the group consisting of histidine (His), phenylalanine (Phe), tyrosine (Tyr), and tryptophan (Trp); 
         AA 5  is selected from the group consisting of arginine (Arg), ornithine (Orn), lysine (Lys), citruline, 2-, 3-, and 4-pyridylalanine, and arginine surrogates; 
         AA 6  is selected from the group consisting of aspartic acid (Asp), asparagine (Asn), glutamic acid (Glu), glutamine (Gln), serine (Ser), 3-amino-5-phenylpentanoic acid, and Phe; 
         AA 7  is selected from the group consisting of no residue, Tyr, and Phe; 
         AA 8  is selected from the group consisting of no residue, Lys, Leu, and Tyr; and 
         Z is attached to the carboxy-terminus of said peptide and is selected from the group consisting of, a hydroxyl group, NH 2 , and aromatic and aliphatic amines; and 
         (d) a compound of Formula V:
   Y-BTM-AA1-AA2-AA3-Z  (V)
 
 
         wherein Y is attached to the amino-terminus of the peptide and is selected from the group consisting of a hydrogen atom, an acyl group (R—CO—) wherein R is a hydrophobic moiety, and an aroyl group (Ar—CO—) wherein Ar is an aryl group; 
         BTM (beta turn mimetic) is a dipeptide surrogate; 
         AA 1  is selected from the group consisting of Arg, Orn, Lys, citruline, 2-, 3-, and 4-pyridylalanine, and arginine surrogates; 
         AA 2  is selected from the group consisting of Asp, Asn, Glu, Gln, Ser, 3-amino-5-phenylpentanoic acid, and Phe; 
         AA 3  is selected from the group consisting of no residue, Tyr, and Phe; and 
         Z is selected from the group consisting of no residue, a hydroxyl group, NH 2 , and aromatic, heteroaromatic, and aliphatic amines. 
       
     
     
         65 . The method of  claim 13 , wherein the FP receptor antagonist is selected from:
 (a) a compound of Formula I or Formula II:   
       
         
           
           
               
               
           
         
         wherein R is selected from the group consisting of CO 2 H, C(O)NHOH, CO 2 R 1 , CH 2 OH, S(O) 2 R 1 , C(O)NHR 1 , P(O)(OR 1 )R 2 , C(O)NHS(O) 2 R 1 , and tetrazole; 
         R 1  and R 2  are independently selected from the group consisting of a hydrogen atom, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, aromatic groups, substituted aromatic groups, carbocyclic groups, substituted carbocyclic groups, heterogeneous groups, substituted heterogeneous groups, heterocyclic groups, substituted heterocyclic groups, heteroaromatic groups, and substituted heteroaromatic groups; 
         W is —CH 2 —, —O—, or —S(O) 2 —; and 
         X is halogen, lower alkyl, alkoxy, or hydrogen; 
         (b) a compound of Formula III: 
       
       
         
           
           
               
               
           
         
         wherein G is selected from the group consisting of substituted or unsubstituted C 1 -C 6 -alkyl aryl, substituted or unsubstituted C 1 -C 6 -alkyl heteroaryl, substituted or unsubstituted C 1 -C 6 -alkyl cycloalkyl, substituted or unsubstituted C 1 -C 6 -alkyl heteroaryl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 -cycloalkyl or C 3 -C 8 -heterocycloalkyl, wherein said cycloalkyl or aryl or heteroaryl groups may be fused with cycloalkyl or aryl or heteroaryl groups; 
         R 1  is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 -cycloalkyl or C 3 -C 8 -heterocycloalkyl, wherein said (hetero)cycloalkyl or aryl or heteroaryl groups may be fused with (hetero)-cycloalkyl or aryl or heteroaryl groups; 
         R 2  is H, carboxy, acyl, alkoxycarbonyl, aminocarbonyl, substituted or unsubstituted C 1 -C 5 -alkyl carboxy, substituted or unsubstituted C 1 -C 5 -alkyl acyl, substituted or unsubstituted C 1 -C 5 -alkyl alkoxycarbonyl, substituted or unsubstituted C 1 -C 5 -alkyl aminocarbonyl, substituted or unsubstituted C 1 -C 5 -alkyl acyloxy, substituted or unsubstituted C 1 -C 5 -alkyl acylamino, substituted or unsubstituted C 1 -C 5 -alkyl ureido, substituted or unsubstituted C 1 -C 5 -alkyl amino, substituted or unsubstituted C 1 -C 5 -alkyl alkoxy, substituted or unsubstituted C 1 -C 5 -alkyl sulfanyl, substituted or unsubstituted C 1 -C 5 -alkyl sulfinyl, substituted or un substituted C 1 -C 5 -alkyl sulfonyl, substituted or unsubstituted C 1 -C 5 -alkyl sulfonylamino, substituted or unsubstituted C 1 -C 5 -alkyl sulfonyloxy, substituted or unsubstituted C 1 -C 6 -alkyl, substituted or unsubstituted C 2 -C 6 -alkenyl, substituted or unsubstituted C 2 -C 6 -alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 -cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted C 1 -C 6 -alkyl aryl, substituted or unsubstituted C 2 -C 6 -alkyl heteroaryl, substituted or unsubstituted C 1 -C 6 -alkyl cycloalkyl, substituted or unsubstituted C 1 -C 6 -alkyl heterocycloalkyl, substituted or unsubstituted C 2 -C 6 -alkenyl aryl, substituted or unsubstituted C 2 -C 6 -alkenyl heteroaryl, substituted or unsubstituted C 2 -C 6 -alkynyl aryl, or substituted or unsubstituted C 2 -C 6 -alkynyl heteroaryl, or wherein R 2  and G may form a C 3 -C 8 -cycloalkyl ring; 
         R 4  is selected from the group consisting of substituted or unsubstituted C 1 -C 6 -alkyl, substituted or unsubstituted C 2 -C 6 -alkenyl, substituted or unsubstituted C 2 -C 6 -alkynyl; and 
         n is an integer from 0 to 2; 
         (c) a compound of Formula IV:
   Y-AA 1 -AA 2 -AA 3 -AA 4 -AA 5 -AA 6 -AA 7 -AA 8 -Z  (IV)
 
 
         wherein Y is attached to the amino-terminus of said peptide and is selected from the group consisting of a hydrogen atom, an acetyl group, a benzoyl group, an acyl group (R—CO—) wherein R is a hydrophobic moiety, and an aroyl group (Ar—CO—) wherein Ar is an aryl group; 
         AA 1  and AA 2  are independently selected from the group consisting of no residue, isoleucine (Ile), leucine (Leu), and related alpha-amino acids possessing hydrophobic side-chains; 
         AA 3  is selected from the group consisting of no residue, glycine (Gly), alanine (Ala), and proline (Pro); 
         AA 4  is selected from the group consisting of histidine (His), phenylalanine (Phe), tyrosine (Tyr), and tryptophan (Trp); 
         AA 5  is selected from the group consisting of arginine (Arg), ornithine (Orn), lysine (Lys), citruline, 2-, 3-, and 4-pyridylalanine, and arginine surrogates; 
         AA 6  is selected from the group consisting of aspartic acid (Asp), asparagine (Asn), glutamic acid (Glu), glutamine (Gln), serine (Ser), 3-amino-5-phenylpentanoic acid, and Phe; 
         AA 7  is selected from the group consisting of no residue, Tyr, and Phe; 
         AA 8  is selected from the group consisting of no residue, Lys, Leu, and Tyr; and 
         Z is attached to the carboxy-terminus of said peptide and is selected from the group consisting of, a hydroxyl group, NH 2 , and aromatic and aliphatic amines; and 
         (d) a compound of Formula V:
   Y-BTM-AA1-AA2-AA3-Z  (V)
 
 
         wherein Y is attached to the amino-terminus of the peptide and is selected from the group consisting of a hydrogen atom, an acyl group (R—CO—) wherein R is a hydrophobic moiety, and an aroyl group (Ar—CO—) wherein Ar is an aryl group; 
         BTM (beta turn mimetic) is a dipeptide surrogate; 
         AA 1  is selected from the group consisting of Arg, Orn, Lys, citruline, 2-, 3-, and 4-pyridylalanine, and arginine surrogates; 
         AA 2  is selected from the group consisting of Asp, Asn, Glu, Gln, Ser, 3-amino-5-phenylpentanoic acid, and Phe; 
         AA 3  is selected from the group consisting of no residue, Tyr, and Phe; and 
         Z is selected from the group consisting of no residue, a hydroxyl group, NH 2 , and aromatic, heteroaromatic, and aliphatic amines. 
       
     
     
         66 . The method of  claim 16 , wherein the FP receptor antagonist is selected from:
 (a) a compound of Formula I or Formula II:   
       
         
           
           
               
               
           
         
         wherein R is selected from the group consisting of CO 2 H, C(O)NHOH, CO 2 R 1 , CH 2 OH, S(O) 2 R 1 , C(O)NHR 1 , P(O)(OR 1 )R 2 , C(O)NHS(O) 2 R 1 , and tetrazole; 
         R 1  and R 2  are independently selected from the group consisting of a hydrogen atom, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, aromatic groups, substituted aromatic groups, carbocyclic groups, substituted carbocyclic groups, heterogeneous groups, substituted heterogeneous groups, heterocyclic groups, substituted heterocyclic groups, heteroaromatic groups, and substituted heteroaromatic groups; 
         W is —CH 2 —, —O—, or —S(O) 2 —; and 
         X is halogen, lower alkyl, alkoxy, or hydrogen; 
         (b) a compound of Formula III: 
       
       
         
           
           
               
               
           
         
         wherein G is selected from the group consisting of substituted or unsubstituted C 1 -C 6 -alkyl aryl, substituted or unsubstituted C 1 -C 6 -alkyl heteroaryl, substituted or unsubstituted C 1 -C 6 -alkyl cycloalkyl, substituted or unsubstituted C 1 -C 6 -alkyl heteroaryl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 -cycloalkyl or C 3 -C 8 -heterocycloalkyl, wherein said cycloalkyl or aryl or heteroaryl groups may be fused with cycloalkyl or aryl or heteroaryl groups; 
         R 1  is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 -cycloalkyl or C 3 -C 8 -heterocycloalkyl, wherein said (hetero)cycloalkyl or aryl or heteroaryl groups may be fused with (hetero)-cycloalkyl or aryl or heteroaryl groups; 
         R 2  is H, carboxy, acyl, alkoxycarbonyl, aminocarbonyl, substituted or unsubstituted C 1 -C 5 -alkyl carboxy, substituted or unsubstituted C 1 -C 5 -alkyl acyl, substituted or unsubstituted C 1 -C 5 -alkyl alkoxycarbonyl, substituted or unsubstituted C 1 -C 5 -alkyl aminocarbonyl, substituted or unsubstituted C 1 -C 5 -alkyl acyloxy, substituted or unsubstituted C 1 -C 5 -alkyl acylamino, substituted or unsubstituted C 1 -C 5 -alkyl ureido, substituted or unsubstituted C 1 -C 5 -alkyl amino, substituted or unsubstituted C 1 -C 5 -alkyl alkoxy, substituted or unsubstituted C 1 -C 5 -alkyl sulfanyl, substituted or unsubstituted C 1 -C 5 -alkyl sulfinyl, substituted or un substituted C 1 -C 5 -alkyl sulfonyl, substituted or unsubstituted C 1 -C 5 -alkyl sulfonylamino, substituted or unsubstituted C 1 -C 5 -alkyl sulfonyloxy, substituted or unsubstituted C 1 -C 6 -alkyl, substituted or unsubstituted C 2 -C 6 -alkenyl, substituted or unsubstituted C 2 -C 6 -alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 -cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted C 1 -C 6 -alkyl aryl, substituted or unsubstituted C 2 -C 6 -alkyl heteroaryl, substituted or unsubstituted C 1 -C 6 -alkyl cycloalkyl, substituted or unsubstituted C 1 -C 6 -alkyl heterocycloalkyl, substituted or unsubstituted C 2 -C 6 -alkenyl aryl, substituted or unsubstituted C 2 -C 6 -alkenyl heteroaryl, substituted or unsubstituted C 2 -C 6 -alkynyl aryl, or substituted or unsubstituted C 2 -C 6 -alkynyl heteroaryl, or wherein R 2  and G may form a C 3 -C 8 -cycloalkyl ring; 
         R 4  is selected from the group consisting of substituted or unsubstituted C 1 -C 6 -alkyl, substituted or unsubstituted C 2 -C 6 -alkenyl, substituted or unsubstituted C 2 -C 6 -alkynyl; and 
         n is an integer from 0 to 2; 
         (c) a compound of Formula IV:
   Y-AA 1 -AA 2 -AA 3 -AA 4 -AA 5 -AA 6 -AA 7 -AA 8 -Z  (IV)
 
 
         wherein Y is attached to the amino-terminus of said peptide and is selected from the group consisting of a hydrogen atom, an acetyl group, a benzoyl group, an acyl group (R—CO—) wherein R is a hydrophobic moiety, and an aroyl group (Ar—CO—) wherein Ar is an aryl group; 
         AA 1  and AA 2  are independently selected from the group consisting of no residue, isoleucine (Ile), leucine (Leu), and related alpha-amino acids possessing hydrophobic side-chains; 
         AA 3  is selected from the group consisting of no residue, glycine (Gly), alanine (Ala), and proline (Pro); 
         AA 4  is selected from the group consisting of histidine (His), phenylalanine (Phe), tyrosine (Tyr), and tryptophan (Trp); 
         AA 5  is selected from the group consisting of arginine (Arg), ornithine (Orn), lysine (Lys), citruline, 2-, 3-, and 4-pyridylalanine, and arginine surrogates; 
         AA 6  is selected from the group consisting of aspartic acid (Asp), asparagine (Asn), glutamic acid (Glu), glutamine (Gln), serine (Ser), 3-amino-5-phenylpentanoic acid, and Phe; 
         AA 7  is selected from the group consisting of no residue, Tyr, and Phe; 
         AA 8  is selected from the group consisting of no residue, Lys, Leu, and Tyr; and 
         Z is attached to the carboxy-terminus of said peptide and is selected from the group consisting of, a hydroxyl group, NH 2 , and aromatic and aliphatic amines; and 
         (d) a compound of Formula V:
   Y-BTM-AA1-AA2-AA3-Z  (V)
 
 
         wherein Y is attached to the amino-terminus of the peptide and is selected from the group consisting of a hydrogen atom, an acyl group (R—CO—) wherein R is a hydrophobic moiety, and an aroyl group (Ar—CO—) wherein Ar is an aryl group; 
         BTM (beta turn mimetic) is a dipeptide surrogate; 
         AA 1  is selected from the group consisting of Arg, Orn, Lys, citruline, 2-, 3-, and 4-pyridylalanine, and arginine surrogates; 
         AA 2  is selected from the group consisting of Asp, Asn, Glu, Gln, Ser, 3-amino-5-phenylpentanoic acid, and Phe; 
         AA 3  is selected from the group consisting of no residue, Tyr, and Phe; and 
         Z is selected from the group consisting of no residue, a hydroxyl group, NH 2 , and aromatic, heteroaromatic, and aliphatic amines.